48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate… Read More
Six provinces and three territories to provide universal immunization programs for Respiratory Syncytial Virus (RSV) infant protection this respiratory season Beyfortus will also be reimbursed through select private health insurance providers… Read More
SAN FRANCISCO and VANCOUVER, BC — Jade Biosciences, Inc. a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing… Read More
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel… Read More
Rezurock® (belumosudil tablets) now listed for public reimbursement, offering access to adult and pediatric patients 12 years and older with chronic GVHD after failure of at least two prior lines of… Read More
